Breast cancer: Genetic signature might spare 100,000 women annually from chemotherapy (Nature Clinical Practice Oncology)

Adjuvant chemotherapy can benefit a subset of patients with early stage breast cancer, and is typically allocated to those deemed to be at a high clinical risk of distant metastasis. This risk can be determined using various algorithms incorporating disease characteristics (such as intrinsic molecular